This is a South Africa news story, published by Science News, that relates primarily to the antiviral drug lenacapavir news.
For more South Africa news, you can click here:
more South Africa newsFor more disease research news, you can click here:
more disease research newsFor more news from Science News, you can click here:
more news from Science NewsOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like disease research news, you might also like this article about
new HIV infections. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest antiviral drug lenacapavir news, yearly preventive medicine news, disease research news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
HIVScience News
•81% Informative
Researchers tested a new formulation of pre-exposure prophylaxis in a clinical trial of HIV-negative cisgender women and teens ages 16 to 25 in South Africa and Uganda .
The Phase III trial compared a twice-yearly injection of the antiviral drug lenacapavir to a widely used daily PrEP pill.
VR Score
85
Informative language
86
Neutral language
50
Article tone
formal
Language
English
Language complexity
61
Offensive language
likely offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
medium-lived
External references
2
Source diversity
2
Affiliate links
no affiliate links